English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    HomeNewsBusinessUSFDA gives nod to Zydus Cadila's overactive bladder tablets

    USFDA gives nod to Zydus Cadila's overactive bladder tablets

    In a filing to the BSE today, the company said it "has received the final approval from the USFDA to market oxybutynin chloride extended-release tablets in the strength of 5 mg, 10 mg, 15 mg".

    June 28, 2017 / 12:06 IST
    Myth 3: Everyone who has a mental illness needs medication to manage symptoms | Bulthuis says no two patients are the same. While medicines can help manage symptoms, there are some people with mental illness who do not require medication. For others, medicine is essential for recovery. (Representative image)

    Myth 3: Everyone who has a mental illness needs medication to manage symptoms | Bulthuis says no two patients are the same. While medicines can help manage symptoms, there are some people with mental illness who do not require medication. For others, medicine is essential for recovery. (Representative image)

    The US Food and Drug Administration (USFDA) has given final approval to drug firm Zydus Cadila to market oxybutynin chloride tablets used to treat symptoms of overactive bladder and urinary incontinence.

    In a filing to the BSE today, the company said it "has received the final approval from the USFDA to market oxybutynin chloride extended-release tablets in the strength of 5 mg, 10 mg, 15 mg".

    The drug is used to take care of an overactive bladder and urinary incontinence (urine leakage) and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad.

    The group now has over 120 approvals and so far filed over 300 ANDAs (abbreviated new drug applications) since the commencement of the filing process in 2003-04.

    first published: Jun 28, 2017 11:45 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347